Next-generation sequencing of human tumours has refined our understanding of the mutational processes operative in cancer initiation and progression, yet major questions remain regarding the factors that induce driver mutations and the processes that shape mutation selection during tumorigenesis. Here we performed whole-exome sequencing on adenomas from three mouse models of non-small-cell lung cancer, which were induced either by exposure to carcinogens (methyl-nitrosourea (MNU) and urethane) or by genetic activation of Kras (Kras LA2 ). Although the MNU-induced tumours carried exactly the same initiating mutation in Kras as seen in the Kras LA2 model (G12D), MNU tumours had an average of 192 non-synonymous, somatic single-nucleotide variants, compared with only six in tumours from the Kras LA2 model. By contrast, the Kras LA2 tumours exhibited a significantly higher level of aneuploidy and copy number alterations compared with the carcinogen-induced tumours, suggesting that carcinogen-induced and genetically engineered models lead to tumour development through different routes. The wild-type allele of Kras has been shown to act as a tumour suppressor in mouse models of non-small-cell lung cancer. We demonstrate that urethaneinduced tumours from wild-type mice carry mostly (94%) Kras Q61R mutations, whereas those from Kras heterozygous animals carry mostly (92%) Kras Q61L mutations, indicating a major role for germline Kras status in mutation selection during initiation. The exomewide mutation spectra in carcinogen-induced tumours overwhelmingly display signatures of the initiating carcinogen, while adenocarcinomas acquire additional C . T mutations at CpG sites. These data provide a basis for understanding results from human tumour genome sequencing, which has identified two broad categories of tumours based on the relative frequency of single-nucleotide variations and copy number alterations 1 , and underline the importance of carcinogen models for understanding the complex mutation spectra seen in human cancers.
Next-generation sequencing of human tumours has refined our understanding of the mutational processes operative in cancer initiation and progression, yet major questions remain regarding the factors that induce driver mutations and the processes that shape mutation selection during tumorigenesis. Here we performed whole-exome sequencing on adenomas from three mouse models of non-small-cell lung cancer, which were induced either by exposure to carcinogens (methyl-nitrosourea (MNU) and urethane) or by genetic activation of Kras (Kras LA2 ). Although the MNU-induced tumours carried exactly the same initiating mutation in Kras as seen in the Kras LA2 model (G12D), MNU tumours had an average of 192 non-synonymous, somatic single-nucleotide variants, compared with only six in tumours from the Kras LA2 model. By contrast, the Kras LA2 tumours exhibited a significantly higher level of aneuploidy and copy number alterations compared with the carcinogen-induced tumours, suggesting that carcinogen-induced and genetically engineered models lead to tumour development through different routes. The wild-type allele of Kras has been shown to act as a tumour suppressor in mouse models of non-small-cell lung cancer. We demonstrate that urethaneinduced tumours from wild-type mice carry mostly (94%) Kras Q61R mutations, whereas those from Kras heterozygous animals carry mostly (92%) Kras Q61L mutations, indicating a major role for germline Kras status in mutation selection during initiation. The exomewide mutation spectra in carcinogen-induced tumours overwhelmingly display signatures of the initiating carcinogen, while adenocarcinomas acquire additional C . T mutations at CpG sites. These data provide a basis for understanding results from human tumour genome sequencing, which has identified two broad categories of tumours based on the relative frequency of single-nucleotide variations and copy number alterations 1 , and underline the importance of carcinogen models for understanding the complex mutation spectra seen in human cancers.
Sequencing studies of human cancers have identified a number of mutation 'signatures', suggesting that tumours carry an imprint of the environmental agents to which patients were exposed 2-4 . At present, there are no studies of genome-wide carcinogen signatures in any mouse cancer models, despite widespread use of these models in studies of cancer. To address the importance of engineered versus carcinogen-induced mutations, we investigated the mutations in mouse non-small-cell lung carcinoma (NSCLC) arising as a result of spontaneous oncogenic activation of Kras (Kras LA2 ) 5 , or exposure to urethane or MNU 6 . Both carcinogens initiate lung tumorigenesis by oncogenic mutation of Kras, which is frequently mutated in human NSCLC 7 . Whole-exome sequencing (WES) was performed on 82 lung adenomas from FVB/N mice, 44 induced by urethane, 26 by MNU, and 12 by the Kras LA2 allele (Extended Data Table 1 ). To study the tumour suppressive role of wild-type Kras, we included mice with one functionally null Kras allele, Kras 1/LSL-G12D (see Methods) 8 , hereafter referred to as Kras 1/2 . Importantly, these mice develop more and larger tumours than wild-type littermates after carcinogen treatment 9,10 .
Carcinogen-induced tumours had far more single-nucleotide variations (SNVs) than Kras LA2 tumours (Fig. 1a) , with an average of 728 and 185 in MNU-and urethane-induced tumours, respectively, and 47 in Kras LA2 tumours. This is similar to findings in humans, in which lung tumours from smokers contained orders of magnitude more SNVs than tumours from non-smokers 11 . We performed hierarchical clustering on the 96 possible SNVs, classified by trinucleotide context and substitution 3 , and found that tumours cluster perfectly by treatment ( Fig. 1b) , underscoring distinct mutational spectra. Highly consistent signatures are apparent across all tumours of each carcinogen group ( Fig. 1c and Extended Data Fig. 1a, b ), in agreement with the known A . T, A . G, and G . A substitutions induced by urethane 12 , and G . A transitions induced by MNU 13 . The elevated SNV burden and clear carcinogen imprint show that most SNVs were induced during the period of carcinogen activity after administration. By contrast, Kras LA2 tumours showed no notable signatures (Extended Data Fig. 1c) .
A highly significant 59-flanking purine bias and 39-flanking thymidine bias for G . A transitions was identified in the MNU-induced tumours (Extended Data Fig. 2a ). Indeed, GGT . A is the most frequent SNV in this group. In urethane-induced tumours, a slight bias for 39cytidine in A . G transitions and 39-guanosine in A . T transversions was seen (Extended Data Fig. 2b, c) , while G . A transitions were also common (Extended Data Fig. 2d ). The most frequent SNVs in Kras LA2 tumours were CGN . A (or the complement, NCG . T) (Extended Data Fig. 2e ). Importantly, CGN . A is a signature of genomic instability in cancer and normal cells 3,14,15 .
In concordance with the propensity of MNU to induce GGT . A transitions, 25/26 MNU-induced lung tumours carried this transition in codon 12 of Kras, resulting in a G12D mutation, while all 44 urethaneinduced tumours harboured Kras Q61 mutations ( Supplementary Table 1 ). Histological evaluation revealed the expected tumour types (Extended Data Fig. 3a ), and solid tumours were significantly enriched in the MNU and Kras LA2 groups, which share the Kras G12D mutation (Extended Data Fig. 3b ). It is possible that Kras G12D initiates a pathway to solid NSCLC that is distinct from that initiated by Q61 mutants. Alternatively, urethane may induce Kras mutations in a different population of tumour-initiating cells. Remarkably, urethane-induced tumours from wild-type mice had almost exclusively Kras Q61R mutations, whereas tumours from Kras 1/2 mice had almost exclusively Q61L mutations (Extended Data Fig. 4a, b ). This switch is probably not due to differences in carcinogen metabolism or DNA repair, as neither the overall mutation spectra (Extended Data Fig. 1b ) nor the exome-wide rates of the causative Q61R and Q61L substitutions (Extended Data Fig. 4c ) differed between tumours of the two genotypes. This suggests that Kras Q61R and Q61L are functionally distinct, and that the selection of cells harbouring these oncoproteins is modulated by wild-type Kras. Intriguingly, in the single instance of a Kras Q61L mutant tumour from a wildtype mouse, a Kras loss-of-function mutation (T35A) 16,17 was also found, potentially inactivating the wild-type allele. Although KRAS Q61 mutations are relatively rare in human lung cancer, further investigation of the Q61 switch may yield valuable insights into RAS mutation selection, and the interplay of RAS oncogenes and their proto-oncogenes. Although further studies are needed to identify the mechanism of this selection, we conclude that Kras mutations are not only carcinogen-dependent, but are influenced by germline differences that alter the expression of wild-type Kras.
We focused our search for additional driver mutations on genes known to harbour bona fide driver mutations in human cancers 18, 19 (see Methods) . Sixty-five consequential SNVs in 49 of these genes were validated (Extended Data Table 2 ), most involving amino acids conserved between mouse and human. SNVs in Akt1, Atm, Rnf43, Notch1, Ret and Rb1, in particular, occurred at positions homologous to mutations in human cancers ( Supplementary Table 2 ). Two nonsense and two missense mutations were found in Mtus1, a candidate tumour suppressor gene in multiple cancers 20-23 . In concordance with its role as a tumour suppressor, knockdown of Mtus1 accelerated growth in a mouse lung cancer cell line driven by Kras G12D (Extended Data Fig. 5a, b ). In addition, MTUS1 expression is significantly and positively associated with overall survival across all stages in human lung adenocarcinoma (The Cancer Genome Atlas (TCGA) Human Lung Adenocarcinoma (LUAD) data set RNA-seq, n 5 354) (Extended Data Fig. 5c and Supplementary  Table 3 ). This association was validated in an independent human lung adenocarcinoma data set 24 ( Supplementary Table 3 ).
The observation that Kras LA2 tumours have on average 15-fold fewer SNVs than MNU-induced tumours (Fig. 1b ), despite sharing similar histology and the same Kras mutation, suggested that there are additional factors influencing tumorigenesis in these samples. Indeed, we found that copy number alterations (CNAs) are widespread in Kras LA2 tumours (average 5 3.25) but infrequent in carcinogen-induced tumours (average 5 0.07), and hierarchical clustering by copy-number profile clearly segregated the carcinogen-induced and Kras LA2 tumours into different groups (Fig. 2 ). Most Kras LA2 tumours (9/12) showed amplification of Kras, mainly via gain of one copy of chromosome 6. These tumours also carried common gains on chromosomes 2, 10, 12, 15 and 17, and deletions on chromosomes 4, 9, 11 and 17 (Extended Data Fig. 6 ), consistent with previously published array comparative genomic hybridization results from the Kras LA2 model 25 . By contrast, carcinogen-induced tumours had very few CNAs and aneuploidies.
A summary of SNVs and CNAs involving driver genes reveals that all SNVs occurred in carcinogen-induced tumours and overwhelmingly showed the signature of the initiating carcinogen ( Fig. 3 ). This suggests that carcinogen models produce tumours with a diversity of potential secondary driver SNVs, recapitulating in part the mutational heterogeneity seen in human cancer. One MNU-induced tumour harboured an E40K mutation in Akt1, generating a constitutively active oncoprotein 26 , and an early nonsense mutation in the tumour suppressor gene Pax5. Together with Kras G12D, this tumour had three functional mutations in cancer drivers, all MNU signature mutations probably induced in the same cell after MNU treatment. Although the Kras LA2 tumours had no SNVs in established driver genes, some exhibited CNAs involving driver genes mutated in the carcinogen-induced tumours (Fig. 3 ). Further evidence for the role of CNAs in genetically engineered mouse models of cancer is provided by a recent report showing that mouse small-cell lung cancers induced by inactivation of Trp53 and Rb1 exhibit many CNAs, but a paucity of SNVs 27 . Similarly, mouse lung tumours induced by Cre activation of Kras LSL-G12D exhibit extremely few exome-wide SNVs (T. Jacks, personal communication). We conclude that carcinogen and genetic models show fundamental differences in patterns of genomic alterations, and that the requirement for CNAs may be abrogated by the high frequency of carcinogen-induced SNVs-a reciprocal relationship also seen in a recent analysis of TCGA sequencing of several thousand human tumours 1 .
To understand the processes operative in progression to adenocarcinoma, we performed WES on 9 FVB/N and 13 A/J strain urethaneinduced, histologically confirmed lung adenocarcinomas (Extended Data Fig. 7a, b ). The observed urethane signature A . G and A . T substitutions recapitulate the rates and patterns seen in the adenomas with remarkable fidelity (Extended Data Fig. 8 ), validating the utility of mouse carcinogen models to resolve complex mutational spectra. Further analysis revealed a significant increase in the CGN . A signature of genomic instability in both FVB/N and A/J adenocarcinomas (Fig. 4 ). This increase cannot be attributed to tumour age, as the FVB/N adenocarcinomas Figure 1 | Differences in mutation burden and spectra between carcinogen and genetic models. a, Total SNVs per tumour. Light shades denote Kras 1/2 genotype. All comparisons of SNVs between treatment groups were significant (P # 1.0 3 10 26 , Wilcoxon rank-sum test, Holm's correction). No significant differences were observed between wild-type and Kras 1/2 tumours. b, Unsupervised, hierarchical clustering of tumours by trinucleotide context substitutions. c, Stacked heatmaps of mutation spectra for five representative MNU-induced and urethaneinduced tumours (see Extended Data Fig. 1 for all tumours). Substitutions are shown below each heatmap, with the 59-and 39-flanking base displayed on top and right, respectively.
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and adenomas were harvested at the same time point (20 weeks) after carcinogen treatment.
Most adenocarcinomas harboured Q61R mutations in Kras (Supplementary Table 4 ). Although urethane is known to induce Kras Q61L lung adenomas in A/J mice, adenocarcinomas from these animals harbour predominantly Kras Q61R mutations 28 . Eleven additional SNVs in driver genes were identified, as well as three SNVs in the reported mouse lung adenoma suppressor gene Fat4 (Supplementary Table 5 ) 29 . Compared with the urethane-induced adenomas, the adenocarcinomas are enriched for tumours with SNVs in high-likelihood driver genes other than Kras (Fisher P 5 0.046), as well as tumours harbouring CGN . A transitions in these genes (Fisher P 5 0.034). These data suggest that CGN . A transitions may play a part in the progression of adenomas to adenocarcinomas. Figure 2 | Distinct copy number profiles of genetically and chemically induced tumours. Unsupervised, hierarchical clustering of log 2 -transformed read count ratios. Kras LA2 tumours showed a significantly higher number of CNAs compared with carcinogen-induced tumours (P 5 4.3 210 , Wilcoxon rank-sum test). Chromosomes are aligned head to tail on the x axis, starting on the left. Samples are labelled by treatment and genotype, with Kras 1/2 samples appearing as light blue and light red. Sample SNV burden is displayed along the y axis in greyscale.
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A comparison of all validated carcinogen-induced mouse mutations with WES of human lung adenocarcinoma (TCGA LUAD, n 5 230) revealed substantial overlap in driver genes harbouring consequential mutations, both overall and in KRAS-mutant tumours (Supplementary Table 6 ). Some of the most frequently mutated genes in the mouse tumours (Arid1b, Atm, Crebbp, Mll2 (also known as Kmt2d), Rb1) were also frequently mutated in the human tumours. Many of the mouse mutations occurred near mutations identified in TCGA LUAD, including functional mutations in Akt1, Atm and Cbl (Supplementary Table 7 ). In addition, the driver genes ALK, APC, JAK2, MET and NF1, commonly mutated in human NSCLC 11 , were mutated in the mouse tumours. Finally, an analysis of MTUS1 mutations in TCGA LUAD revealed only consequential mutations (1.7%)-two missense mutations, and two frameshift deletions-suggesting that loss-of-function mutations in MTUS1 may be selected for in a subset of lung adenocarcinomas.
Genomic analysis of mouse tumours induced by a range of carcinogens may help reveal the relationships between environmental exposures and tumour architecture. Models that encompass heterogeneity in both genetic background and carcinogen exposure may also be useful for preclinical testing of cancer therapeutics, including immunotherapy, as the diversity of germline and somatic SNVs may recapitulate the variation in drug response and resistance observed in human clinical trials. Importantly, carcinogen models enable the production of tumours with a range of initiating Ras lesions, providing a valuable resource for interrogating the specificity and idiosyncrasies of these different mutations.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Mouse strains and tumour induction. Kras LA2 and Kras LSL-G12D alleles, originally on a C57BL6/129/SvJae background, were backcrossed onto the FVB/N genetic background for more than 20 generations. Mice were treated with urethane (1 g kg 21 ) or MNU (50 mg kg 21 ) dissolved in PBS by intraperitoneal injection at ,7-12 weeks of age. Lung tumours from mice induced with carcinogen were harvested at ,20 weeks after injection, or ,32 weeks in the A/J animals, while spontaneous lung tumours were collected from Kras LA2 mice at ,9 months of age. For the urethane-induced adenomas, 18 tumours from seven wild-type animals and 26 tumours from nine Kras LSL-G12D animals were collected. For the MNU treatment group, 5 tumours from four wild-type animals and 21 tumours from three Kras LSL-G12D animals were collected. A total of 12 tumours were collected from four Kras LA2 animals. Eight histologically confirmed adenocarcinomas were collected from four FVB/N Kras LSL-G12D animals, and one from a wild-type FVB/N animal. Thirteen tumours, including ten histologically confirmed adenocarcinomas, were collected from seven wild-type A/J animals. Kras LSL-G12D is a latent G12D allele that is inactive in the absence of Crerecombinase. Importantly, lungs from Kras LSL-G12D heterozygous mice were shown to have an approximately twofold reduction of Kras messenger RNA transcript and protein compared with wild-type littermates 30 . Furthermore, these mice had more and larger lung tumours than wild-type mice after carcinogen treatment 30 , similar to the results seen for animals heterozygous for the original Kras null allele 31 .
No animals or tumours were excluded from the analysis. Tumours were collected from male and female mice, and no sex differences were observed. No formal randomization was performed, and all analyses were performed against the entire set of data in an unbiased manner. All animal experiments were approved by the University of California San Francisco Laboratory Animal Resource Center. DNA isolation and sequencing. Formalin-fixed or flash-frozen tumours free of visible normal tissue were digested overnight in proteinase K (Bioline) and phenol/ chloroform purified using 5 PRIME Phase Lock Gel Heavy Tubes (Fisher Scientific). Integrity of genomic DNA was assessed by electrophoresis on 1% agarose gels, and concentration was determined by nanodrop spectrophotometry and PicoGreen (Invitrogen). Exome enrichment and sequencing genomic libraries were prepared using the Illumina Paired End Sample Prep Kit following the manufacturer's instructions. Enrichment was performed as described previously 32 using the Agilent SureSelect Mouse All Exon kit following the manufacturer's recommended protocol. Each exome was sequenced using a 76 bp paired-end protocol on the Illumina platform (GAII or HiSeq2000). Sequence alignment, processing and quality control. Tumour .bam files were aligned to the GRCm38/mm10 version of the Mus musculus genome using BWA (version 0.5.9) 33 . After alignment, duplicates were marked and mate information was fixed using Picard (version 1.80; http://broadinstitute.github.io/picard/). We then recalibrated base quality score and realigned reads around indels using GATK (version 2.2-15) 34 . Finally, alignment and coverage metrics were collected using Picard. We sequenced an average of 75 million unique on-target reads per tumour. Targeted bases were sequenced to a mean depth of 72, and more than 88% of targeted bases were sequenced to 203 coverage or greater. There were no significant differences in depth of coverage or proportion of regions covered to 203 between tumour induction groups. Identification of SNVs and annotation. SNVs were identified using the somatic variant detection program, MuTect (version 1.1.4) 35 . Tumours were called against DNA taken from normal tail isolated from two wild-type FVB/N control samples. GRCm38/mm10 served as the reference during calling. Each set of variants was then subset to those variants that passed MuTect filters and had a minimum read depth of 12. The intersection of both callsets was then filtered for known variants from the database of mouse variation available at http://ftp-mouse.sanger.ac.uk (release 1303, mgp.v3). Variants found only in Mus spretus, Mus castaneus or Mus musculus musculus were not used for filtration. All samples were also filtered for variants observed in a panel of six controls. These comprised the two wild-type samples used for variant calling, two Kras LA2 mice, and two Kras LSL-G12D heterozygous mice. These mice were then called for variants using FreeBayes (version 0.9.8; http://arxivorg/ abs/1207.3907), UnifiedGenotyper (version 2.2-15) 34 and mpileup (version 0.1.18) 36 . Variants from each caller were then filtered for sites with a minimum quality of 50 and minimum depth of 10. Variants called by a minimum of two callers were used to filter variants. Surviving variants were annotated using Annovar (downloaded on 5 September 2013) 37 . A final level of filtration was performed on variants that showed clear clustering by mouse, which were called SNPs and discarded. In Kras LSL-G12D mice, MNU-induced G12D mutation of the wild-type allele was clearly distinguished from latent G12D on the Kras LSL-G12D allele by observation of a nearby SNP, unique to the Kras LSL-G12D allele, in the exome-sequencing reads as well as Sanger sequencing. Mutation spectra analysis. SNVs in all tumours were annotated by the 96 possible trinucleotide context substitutions (6 types of substitutions 3 4 possible flanking 59 bases 3 4 possible flanking 39 bases) and summed in each tumour, creating a matrix of 82 tumours 3 96 substitutions. For hierarchical clustering, these counts were converted to per tumour proportions and clustered by Euclidean distance and similarity computed by nearest neighbour in R. For heatmaps in Fig. 1c and Extended Data Fig. 1 , substitution counts were log 10 normalized, column scaled and centred on 0. Mutation spectra barplots were created by dividing each totalled type of substitution in each tumour by the total number of successfully sequenced contexts (defined as $103 coverage) in that tumour corresponding to each substitution, retrieved from mpileup of the .bams in samtools. The resulting per tumour substitution rates were then averaged across all tumours in the respective treatment groups. Prioritization of high-likelihood driver genes. We explored a recently published gene prioritization approach that specifically addresses the phenomenon of spurious enrichment of longer genes by adjusting for gene expression and replication timing 4 . However, given the scarcity of recurrent variants in our data set limiting the utility of this approach, we decided to prioritize variants that occurred in genes described by Vogelstein and colleagues as known to harbour bona fide driver mutations in cancer 19 , as well as the recently identified lung cancer driver genes Fgfr4, Map3k9 and Pak5 (ref. 18). In particular, Vogelstein et al. described a stringent list of 125 driver genes harbouring subtle mutations based on the criteria that .20% recorded mutations in oncogenes must be recurrent and missense, and .20% recorded mutations in tumour suppressors must be inactivating. Mtus1 was chosen for further investigation owing to the recurrence of missense and nonsense mutations. Variants were compared to known human somatic mutations as available via the COSMIC database 38 . Briefly, the mouse and human sequences for homologous proteins were pairwise aligned using Clustal Omega 39 and the human protein position homologous to the mouse mutation was used to query COSMIC for known missense and nonsense mutations at or surrounding this peptide position. Local conservation was determined after sequence alignment using a 6 10 amino acid residue window surrounding the substituted amino acid. Validation of SNVs. SNVs were validated by either Sequenom MassARRAY or conventional Sanger sequencing. SNVs were called validated if they were detected in the tumour but not in matched normal DNA. A subset of SNVs that failed both methods for technical reasons was called validated if individual inspection of the aligned reads in tumours and controls strongly supported validity, as performed in previous studies 40 . The method used for validation of SNVs in driver genes is noted in Extended Data Table 2 and Supplementary Table 5 . Altogether, validation was attempted on 401 SNVs from the adenomas. A total of 11 failed for technical reasons, and 13 were inconclusive. A total of 17 variants were validated by visual inspection, representing 4.2% of the 401 variants tested. SNVs tested by Sequenom were called inconclusive if the SNV was observed in the tumour but failed in the control, or the SNV was observed in the tumour and not the matched normal control, but was observed in control tissue from another mouse. SNVs tested by visual inspection were called inconclusive if inspection suggested somatic origin, but total variant reads were less than 10. The overall validation rate (excluding inconclusive SNVs) was 87%. The Sequenom validation rate alone was 86%. The vast majority of Kras mutations were validated by Sanger sequencing, although a small subset went undetected by this method ( Supplementary Table 1 ) despite confirmation by manual inspection of the alignments, suggesting a higher sensitivity afforded by WES. These patterns confirm previous results on carcinogen-specific mutations in Kras 6,9,10 . Sanger sequencing validation was attempted on 20 randomly selected CGN . A transitions as well as 3 CGN . A transitions in driver genes in the adenocarcinoma samples, 15 of which passed ( Supplementary Table 8 ). Alignments were visually inspected for the remaining eight, all of which supported somatic origin, but only one of which had enough variant reads ($10) to pass. Interestingly, the inconclusive variants and the majority of the validated variants had very low variant read fractions, supporting a hypothesis that the CGN . A mutations were acquired during progression and are represented in subclonal tumour fractions. Assessment of copy number from read depth. Copy number was estimated from sequencing data using FREEC (version v6.4; http://bioinfo-out.curie.fr/projects/ freec/). Read depth was compared between tumour and control samples to estimate copy number in 8 kb windows, and subsequently segmented via a LASSO-based algorithm 41 . FREEC was run with the following parameters: window size, 8 kb; step size, 2.5 kb; contaminationAdjustment 5 TRUE; noisyData 5 TRUE; BAF calculation activated. 2.5 kb windows were then aggregated into 15 kb bins by taking the median ratio for all covered windows. Each tumour was profiled against the two wild-type controls used for variant calling. Aggregate profiles were generated for each tumour by the following rules: if either ratio was approximately neutral, the region was considered neutral; if both ratios were aberrant with the same directionality, the more conservative ratio was used; if both ratios were aberrant with different directionality, the region was discarded. Resulting merged ratios were then inspected for high missing rates and low variance, which were then omitted. Additionally, several small regions with evidence of technical artefacts resulting in extremely consistent aberration rates (greater than 50% of samples) across all treatment LETTER RESEARCH groups were manually excluded. Particularly, these regions were manually inspected for the existence of large gene families that could account for misalignments and result in spurious aneuploidies. Short spans on chromosomes 1, 4, 6 and 12 were discarded as artefacts. Histological classification. A small piece of each tumour was collected and paraffin embedded for pathology, sectioned to 6 mm and haematoxylin and eosin (H&E) stained. Histological architecture was classified as either papillary, solid, or mixed papillary and solid. Solid was defined as histology with marked lack of papillary structure, yet more structure than traditionally solid lung adenocarcinomas in humans. Adenocarcinomas were called based on large size and the presence of the following cytological criteria: tumour cell crowding, scattered mitotic figures, nuclear atypia (enlargement and moderate pleomorphism), nuclear membrane irregularity, and prominent nucleoli. All histology was called by a lung pathologist blinded to the study groups and conditions. Cell culture, Mtus1 knockdown and MTT assay. The mouse lung cancer cell line K493.1, which harbours a Kras G12D mutation, was grown in DMEM supplemented with 10% fetal bovine serum (Atlas Biologicals). Mtus1 was knocked down using 50 nM ON-TARGETplus SMARTpool siRNA (Dharmacon) containing multiple pooled siRNAs targeting all isoform transcripts of mouse Mtus1 (catalogue number L-065229-01). Transfection of siRNA was performed at ,20-40% cell confluence using Lipofectamine-2000 (Invitrogen). In parallel, cells were transfected with control ON-TARGETplus Non-Targeting Pool siRNA (catalogue number D-001810-10). RNA was harvested from cells at day 3 after transfection using Trizol reagent (Invitrogen), DNA was removed using the TURBO DNA-free kit (Ambion), and complementary DNA was synthesized from 500 ng RNA using the Superscript III First-strand Synthesis kit (Invitrogen). qRT-PCR was performed on cDNA using TaqMan Assays-on-Demand (Applied Biosystems) against mouse Mtus1 (Mm00 628662_m1 Mtus1) and b-actin on the 7900HT Fast Real-Time PCR System (Applied Biosystems). Reactions were performed in quadruplicate, and levels of Mtus1 were normalized to b-actin. Cell proliferation was assayed in 96-well plates (six replicate wells per group) at days 1, 2 and 3 after siRNA transfection using MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Invitrogen). Formazan crystals were re-suspended in dimethylsulphoxide (DMSO), and absorbance was read at 540 nm. Four independent experiments were performed, and a significant increase in absorbance (Wilcoxon rank-sum test) was always seen in the Mtus1 knockdown compared with control siRNA cells at day 3. One representative experiment is shown in Extended Data Fig. 5b . All protocols were performed following the manufacturer's instructions. Survival analyses in human lung cancer data sets. The TCGA LUAD and human lung squamous cell carcinoma (LUSC) data sets were downloaded from the UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu). Illumina HiSeq 2000 RNA Sequencing expression data was used for analyses of gene expression with overall survival. A validation data set for MTUS1 expression in lung adenocarcinoma 24 was downloaded from https://caintegrator.nci.nih.gov/caintegrator/. Analysis of MTUS1 expression and survival was also repeated in a second squamous cell carcinoma (SCC) data set 42 , which was downloaded from the UCSC Cancer Genomics Browser. No association between MTUS1 expression and survival was seen in the SCC data sets ( Supplementary Table 3 ), suggesting that MTUS1 expression may only have prognostic significance in certain types of lung cancer such as NSCLC. For all survival analyses, clinical covariates of sex, age, cigarette pack years smoked and stage were included, except in one data set 24 in which cigarette pack years smoked was not available. Cox regression was performed in R with gene expression as a continuous variable. High and low expression groups were split about median expression values for plotting Kaplan-Meier curves. Human versus mouse mutation comparison. Genes included in this comparison were limited to known driver genes (see earlier) harbouring mutations in the carcinogen-induced mouse tumours. The TCGA LUAD WES .vcf was downloaded from the UCSC Cancer Genomics Browser. Only functional SNVs and indels were included. Validated functional SNVs from carcinogen-induced mouse adenomas and adenocarcinomas, and CNAs from the carcinogen-induced adenomas, were used in the comparison. Inclusion of mouse CNAs (six total) made little difference overall, but were included to emphasize recurrent mutation of Rb1 in the mouse tumours, which had four deletions and two missense SNVs. Generation of plots. All plots were created using the statistical computing language R (http://www.R-project.org/). Heatmaps were generated using the heatmap.2 function in the gplots package (http://cran.r-project.org/web/packages/gplots/index. html), Kaplan-Meier curves were generated using the survival package (http:// CRAN.R-project.org/package5survival), and all other plots were made using the ggplot2 package (http://ggplot2.org/). Statistical analyses. The nonparametric Wilcoxon rank-sum test (Mann-Whitney U test) was used in Figs 1, 2, 4 , and Extended Data Figs 2, 4, 5 for testing the alternative hypothesis that two populations of values differ against the null hypothesis that they are the same. This test was chosen owing to its efficiency in handling both normal and non-normal distributions. The Fisher exact test was used in the text and in Extended Data Figs 3 and 4 to compare count data between groups, and was chosen for its robust ability to handle high and low ranges of count data. Where appropriate, P values were adjusted for multiple tests using the Holm's correction for multiple comparisons. Survival analysis in Extended Data Fig. 5 is explained earlier. All data were visualized in R using summary statistics and basic plotting functions before statistical testing, and variance was comparable in all cases in which the Wilcoxon rank-sum test was used. All assumptions of statistical tests were met. Data deposition. Aside from the raw .bam files (European Nucleotide Archive (ENA) accession ERP001454), a sample ID key with study names and ENA names is provided in Supplementary Information (ExomeLungTumorIDs_Key.txt). Variant call format files of SNVs used in analyses in the paper are provided in Supplementary Information (Adenomas_variants.txt, Adenocarcinomas_variants.txt). specificity in urethane-induced tumours. a, Kras mutant alleles for urethane tumours are plotted as coloured squares for all three oncogenic alleles detected in these tumours. Kras genotype is indicated as either white (wild type (WT)) or black (heterozygous) squares. b, Highly significant switch in Kras codon 61 mutations between tumours from wild-type mice and Kras 1/2 mice (Fisher exact test). c, No significant difference was seen between the exome-wide rates of the substitutions underlying Kras Q61R (CAA . G) and Q61L (CAA . T) mutations between tumours from wild-type and Kras 1/2 mice (Wilcoxon rank-sum test). NS, not significant. trials were performed and growth was significantly increased by day 3 after knockdown in each experiment. One representative trial is shown. c, MTUS1 expression is significantly associated with overall survival in human lung adenocarcinoma (P 5 0.00097, x 2 5 10.9). Analysis was performed using the clinical covariates gender, age, pack years smoked, and stage. 
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